Development of new diets enriched in gut microbial substances to treat cardiovascular disease

Project Lead

Professor Francine Marques, Monash University

Project Team

Associate Professor Sushil Dithal, Monash University; Dr Hamdi Jama, Monash University; Dr Rikeish Muralitharan, Monash University; Dr Smriti Shrestha, Monash University; Dr Simona Antonacci, Monash University

Project Summary

Problem

Many hypertensive patients struggle with inadequate blood pressure control due to side effects and adherence issues associated with current medications. There is a pressing need for effective and well-tolerated non-pharmacological therapies to improve cardiovascular health outcomes"

Solution

This project aims to develop and test new dietary supplements enriched with microbial metabolites, specifically short-chain fatty acids (SCFAs), known for their potential to lower blood pressure. The project will enhance previous products by increasing SCFA levels, improving bioavailability, and reducing supplement volume. Multiple delivery methods will be evaluated to optimise SCFA release and metabolic outcomes

Impact

Successful development of these innovative dietary supplements could significantly impact hypertension management by providing a non-pharmacological approach that enhances patient compliance and improves outcomes. The commercialisation potential is substantial, tapping into a growing market for cardiovascular health supplements. By engaging with consumers and stakeholders, the project ensures that the developed products meet patient preferences and healthcare needs, potentially reducing healthcare costs associated with hypertension management and improving overall quality of life for patients.